A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Japan

Nagoya City University Hospital ( Site 0003), Nagoya, Aichi-ken

National Hospital Organization Kyushu Cancer Center ( Site 0001), Fukuoka